|
A Phase I Study of the Safety and Immunogenicity of rgp 120/HIV-1IIIB Vaccine in HIV-1 Seropositive Adult Volunteers Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or professional assistance by using a genuine doctor. We aren't mDs. Always consult your physician about A Phase I Study of the Safety and Immunogenicity of rgp 120/HIV-1IIIB Vaccine in HIV-1 Seropositive Adult Volunteers conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. A Phase I Study of the Safety and Immunogenicity of rgp 120/HIV-1IIIB Vaccine in HIV-1 Seropositive Adult Volunteers Clinical research trials and A Phase I Study of the Safety and Immunogenicity of rgp 120/HIV-1IIIB Vaccine in HIV-1 Seropositive Adult Volunteers health trials occur in a lot of of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the potency of new does drugs. The role of the studies / undertakings is to figure out specific human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all sorts of conditions, including A Phase I Study of the Safety and Immunogenicity of rgp 120/HIV-1IIIB Vaccine in HIV-1 Seropositive Adult Volunteers. A Phase I Study of the Safety and Immunogenicity of rgp 120/HIV-1IIIB Vaccine in HIV-1 Seropositive Adult Volunteers Clinical Trials and other clinical trials permit volunteers to get medical treatment choices before they are available to the general public. Many times the test subjects get professional assistance for free of charge, and occasionally they are compensated for their time. Sometimes there is a cost for a A Phase I Study of the Safety and Immunogenicity of rgp 120/HIV-1IIIB Vaccine in HIV-1 Seropositive Adult Volunteers clinical trial. Human subjects often get the best healthcare possible for their A Phase I Study of the Safety and Immunogenicity of rgp 120/HIV-1IIIB Vaccine in HIV-1 Seropositive Adult Volunteers condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, medical hazards (perhaps life-threatening), and/or the treatment being ineffectual. Trials are federally governed with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Phase I Study of the Safety and Immunogenicity of rgp 120/HIV-1IIIB Vaccine in HIV-1 Seropositive Adult Volunteers  A Phase I Study of the Safety and Immunogenicity of rgp 120/HIV-1IIIB Vaccine in HIV-1 Seropositive Adult Volunteers
A Phase I Study of the Safety and Immunogenicity of rgp 120/HIV-1IIIB Vaccine in HIV-1 Seropositive Adult Volunteers
For Condition: HIV Infections
Status: Completed
Sponsor(s): Genentech ,
Synopsis: To test the safety and immunogenicity of rgp 120/HIV-1IIIB vaccine in HIV-1 seropositive adult patients.
Details:
Eligibility:
Study Type: Interventional, Prevention
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Patients must have the following: - Stage 1 or 2 Walter Reed clinical staging of HIV infected individuals. - The ability to understand and sign a written informed consent form, which must be obtained prior to study entry. - Be available for 24 weeks so that follow up may be completed. - Qualify for care as Department of Defense health care beneficiary. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: - Prior history of clinically significant cardiac, pulmonary, hepatic, renal, neurologic or autoimmune disease, other than HIV-1 infection, and in less than average general health as determined by a medical history, physical examination, and the required laboratory test results. Concurrent Medication: Excluded: - Corticosteroids or other known immunosuppressive drugs. - Any experimental agents. Patients with the following are excluded: - Prior history of clinically significant cardiac, pulmonary, hepatic, renal, neurologic or autoimmune disease, other than HIV-1 infection, and in less than average general health as determined by a medical history, physical examination, and the required laboratory test results. Prior Medication: Excluded within 30 days of study entry: - Zidovudine or other anti-retroviral agents.
Total Enrollment:
Location and Contact Information:
Walter Reed Army Institute of Research
Rockville, Maryland, 20850
United States
Additional Information:
Study ID Numbers: 075A; V0200g
Study Start Date:
Record last reviewed: August 1992
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001992
Other Hiv Infections Studies:
1. A Study to See if Certain Antioxidants and Vitamins Will Keep Lactate Levels Down in Patients Taking Anti-HIV Drugs
2. Safety of and Immune Response to an HIV-1 DNA Vaccine (VRC HIVDNA009-00-VP) in HIV Uninfected Adults
3. A Pharmacokinetic Study of L-697,661 Alone and in Combination with Zidovudine
4. A Study of the Safety and Effectiveness of a Chickenpox Vaccine in HIV-Infected Children
5. Prevalence of Hepatitis C Virus Infection in HIV-Infected Children
Related Studies:
Other HIV Infections Clinical Trials
Other Maryland Clinical Trials
Other Rockville Clinical Trials
A Phase I Study of the Safety and Immunogenicity of rgp 120/HIV-1IIIB Vaccine in HIV-1 Seropositive Adult Volunteers
|
|
|
|
|
|
|
|
